Advertisement

Suplatast and asthma

NEW YORK, July 24 (Praxis Press) Th2 cytokines are strongly implicated in the immunopathology of asthma. Tamaoki and colleagues evaluated the steroid-sparing effect of suplatast tosilate, a selective Th2 cytokine inhibitor, relative to placebo in patients with steroid-dependent asthma. When steroid doses were halved, patients in the suplatast tosilate group had less deterioration of pulmonary function, asthma symptoms, and reliance on beta2-agonists for relief. These benefits were achieved with

July 25, 2000

NEW YORK, July 24 (Praxis Press) Th2 cytokines are strongly implicated in the immunopathology of asthma. Tamaoki and colleagues evaluated the steroid-sparing effect of suplatast tosilate, a selective Th2 cytokine inhibitor, relative to placebo in patients with steroid-dependent asthma. When steroid doses were halved, patients in the suplatast tosilate group had less deterioration of pulmonary function, asthma symptoms, and reliance on beta2-agonists for relief. These benefits were achieved with few side effects. Suplatast tosilate may allow a reduction of steroid dose in patients with steroid-dependent asthma.

Follow The Scientist

icon-facebook icon-linkedin icon-twitter icon-vimeo icon-youtube
Advertisement

Stay Connected with The Scientist

  • icon-facebook The Scientist Magazine
  • icon-facebook The Scientist Careers
  • icon-facebook Neuroscience Research Techniques
  • icon-facebook Genetic Research Techniques
  • icon-facebook Cell Culture Techniques
  • icon-facebook Microbiology and Immunology
  • icon-facebook Cancer Research and Technology
  • icon-facebook Stem Cell and Regenerative Science
Advertisement
Teknova
Teknova
Advertisement
PITTCON
PITTCON
Life Technologies